T1	PROC 1 123	Trasplante alogénico de células progenitoras hematopoyéticas de sangre periférica con acondicionamiento de baja intensidad
T2	ANAT 25 82	células progenitoras hematopoyéticas de sangre periférica
T3	PROC 129 140	tratamiento
#1	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 145 184	carcinoma de células claras metastásico
#2	AnnotatorNotes T4	C2931852; Clear-cell metastatic renal cell carcinoma; Neoplastic Process
T5	PROC 226 237	seguimiento
#3	AnnotatorNotes T5	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T6	DISO 267 276	toxicidad
#4	AnnotatorNotes T6	C0600688; Toxic effect; Injury or Poisoning
T7	PROC 293 378	transplante alogénico de células progenitoras hematopoyéticas con intensidad reducida
T8	ANAT 318 354	células progenitoras hematopoyéticas
#5	AnnotatorNotes T8	C0018956; Hematopoietic stem cells; Cell
T9	PROC 380 392	mini-alo TMO
T10	DISO 397 424	carcinoma renal metastásico
#6	AnnotatorNotes T10	C2931852; Clear-cell metastatic renal cell carcinoma; Neoplastic Process
T11	PROC 459 480	tratamiento sistémico
T12	PROC 547 560	inmunoterapia
#7	AnnotatorNotes T12	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
T13	PROC 626 638	mini-alo TMO
T14	CHEM 680 691	Fludarabina
#8	AnnotatorNotes T14	C0059985; fludarabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T15	PROC 737 748	infusión IV
#9	AnnotatorNotes T15	C0021440; Intravenous infusion procedures; Therapeutic or Preventive Procedure
T16	CHEM 764 772	Busulfán
#10	AnnotatorNotes T16	C0006463; busulfan; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T17	DISO 1124 1172	enfermedad injerto contra huésped aguda hepática
#11	AnnotatorNotes T17	C1739104; Acute graft versus host disease in liver; Disease or Syndrome
T18	ANAT 1164 1172	hepática
#12	AnnotatorNotes T18	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T19	PROC 1249 1261	mini-alo TMO
T20	DISO 1291 1318	carcinoma renal metastásico
#13	AnnotatorNotes T20	C2931852; Clear-cell metastatic renal cell carcinoma; Neoplastic Process
T21	PROC 1398 1414	ensayos fase III
#14	AnnotatorNotes T21	C0282461; Phase 3 Clinical Trials; Research Activity
T22	ANAT 158 172	células claras
T23	ANAT 407 412	renal
#16	AnnotatorNotes T23	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T24	PROC 642 649	régimen
#17	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	DISO 1100 1108	falleció
#18	AnnotatorNotes T25	C1306577; Death (finding); Finding | C1546956; Patient Outcome - Died; Finding
T26	ANAT 1301 1306	renal
#19	AnnotatorNotes T26	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T28	Duration 214 222	dos años
T29	LIVB 498 507	pacientes
#20	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	Date 567 573	I/2001
T31	Date 576 582	I/2003
T32	LIVB 586 595	pacientes
#21	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T34	Dose 693 701	30 mg/m2
T36	Route 746 748	IV
#22	AnnotatorNotes T36	C1522726; Intravenous Route of Drug Administration; Functional Concept
T37	Duration 752 762	30 minutos
T38	Dose 774 781	1 mg/kg
T39	Frequency 794 806	cada 6 horas
T40	Route 807 811	v.o.
T41	Dose 834 841	4 dosis
T42	Date 845 856	día -6 y -5
T43	Dose 864 871	2 dosis
T44	Dose 879 887	10 dosis
T45	LIVB 915 924	pacientes
#23	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	LIVB 947 955	paciente
#24	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	LIVB 969 978	pacientes
#25	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	LIVB 1026 1035	pacientes
#26	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Duration 1054 1068	más de 6 meses
T50	LIVB 1091 1099	paciente
#27	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Date 1112 1119	día +30
T53	LIVB 1222 1231	pacientes
#28	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Spec_cue 1265 1273	factible
T55	LIVB 1277 1286	pacientes
#29	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T57	PHYS 46 61	hematopoyéticas
#30	AnnotatorNotes T57	C0018951; Hematopoiesis; Organ or Tissue Function
T59	PHYS 339 354	hematopoyéticas
#31	AnnotatorNotes T59	C0018951; Hematopoiesis; Organ or Tissue Function
T60	ANAT 1135 1142	injerto
#32	AnnotatorNotes T60	C0332835; Transplanted tissue; Tissue
T61	LIVB 1150 1157	huésped
#33	AnnotatorNotes T61	C1167395; Host (organism); Organism
T27	Date 705 733	los días -9, -8, -7, -6 y -5
T33	Date 812 832	los días -6, -5 y -4
T35	Date 872 877	el -4
T56	Date 993 996	+30
#34	AnnotatorNotes T56	[Day +30]
T58	Date 999 1002	+60
#35	AnnotatorNotes T58	[Day +60]
A1	Assertion T19 Speculated
T52	CONC 1383 1394	confirmarse
A2	Assertion T52 Speculated
#36	AnnotatorNotes T52	C1456348; Confirm; Qualitative Concept
T62	Spec_cue 1375 1382	debería
R1	Speculation Arg1:T62 Arg2:T52	
T63	CONC 1366 1374	eficacia
A3	Assertion T63 Speculated
#37	AnnotatorNotes T63	C1280519; Effectiveness; Qualitative Concept
R2	Speculation Arg1:T62 Arg2:T63	
R5	Location_of Arg1:T22 Arg2:T4	
R6	Has_Duration_or_Interval Arg1:T5 Arg2:T28	
T64	Quantifier_or_Qualifier 238 244	mínimo
R7	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T64	
#38	AnnotatorNotes T64	C0547040; Minimal; Qualitative Concept
R12	Location_of Arg1:T23 Arg2:T10	
T65	Quantifier_or_Qualifier 437 455	al menos a 1 línea
R13	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T65	
T66	Quantifier_or_Qualifier 425 436	refractario
#39	AnnotatorNotes T66	C0205269; Unresponsive to Treatment; Functional Concept
R14	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T66	
R15	Before Arg1:T11 Arg2:T7	
R16	Causes Arg1:T7 Arg2:T6	
R17	Experiences Arg1:T29 Arg2:T12	
R18	After Arg1:T12 Arg2:T30	
R19	Before Arg1:T12 Arg2:T31	
R20	Experiences Arg1:T32 Arg2:T13	
R21	Before Arg1:T12 Arg2:T13	
R22	After Arg1:T13 Arg2:T30	
R23	Before Arg1:T13 Arg2:T31	
R24	Has_Dose_or_Strength Arg1:T14 Arg2:T34	
R25	Overlap Arg1:T14 Arg2:T27	
R26	Used_for Arg1:T14 Arg2:T15	
R27	Has_Route_or_Mode Arg1:T14 Arg2:T36	
R28	Has_Duration_or_Interval Arg1:T14 Arg2:T37	
R29	Has_Dose_or_Strength Arg1:T16 Arg2:T38	
R30	Has_Frequency Arg1:T16 Arg2:T39	
R31	Has_Route_or_Mode Arg1:T16 Arg2:T40	
R32	Overlap Arg1:T16 Arg2:T33	
R33	Has_Dose_or_Strength Arg1:T16 Arg2:T41	
R34	Overlap Arg1:T16 Arg2:T42	
R35	Has_Dose_or_Strength Arg1:T16 Arg2:T43	
R36	Overlap Arg1:T16 Arg2:T35	
R37	Has_Dose_or_Strength Arg1:T16 Arg2:T44	
T67	Quantifier_or_Qualifier 888 896	en total
R38	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T67	
T68	Observation 979 990	progresaron
#40	AnnotatorNotes T68	C1457868; Worse; Finding (?)
R39	Experiences Arg1:T47 Arg2:T68	
R40	Overlap Arg1:T68 Arg2:T56	
R41	Overlap Arg1:T68 Arg2:T58	
R42	Experiences Arg1:T50 Arg2:T25	
R43	Overlap Arg1:T25 Arg2:T51	
R44	Causes Arg1:T17 Arg2:T25	
R45	Location_of Arg1:T60 Arg2:T17	
R46	Location_of Arg1:T18 Arg2:T17	
R47	Experiences Arg1:T61 Arg2:T17	
R48	Experiences Arg1:T50 Arg2:T17	
T69	Observation 1040 1053	sobrevivieron
R49	Experiences Arg1:T48 Arg2:T69	
R50	Has_Duration_or_Interval Arg1:T69 Arg2:T49	
R51	Speculation Arg1:T54 Arg2:T19	
R52	Experiences Arg1:T55 Arg2:T20	
R53	Location_of Arg1:T26 Arg2:T20	
R54	Experiences Arg1:T55 Arg2:T19	
#41	AnnotatorNotes T67	C0439810; Total; Qualitative Concept
T70	Observation 1189 1208	quimerismo completo
R58	Experiences Arg1:T53 Arg2:T70	
#42	AnnotatorNotes T11	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R3	Before Arg1:T11 Arg2:T9	
#15	AnnotatorNotes T22	C1513940; Neoplastic Clear Cell; Cell (?)
#43	AnnotatorNotes T40	C1527415; Oral Route of Drug administration; Functional Concept
A4	Experiencer T50 Patient
A5	Experiencer T61 Patient
A6	Experiencer T48 Patient
A7	Experiencer T55 Patient
A8	Experiencer T53 Patient
A9	Experiencer T29 Patient
A10	Experiencer T32 Patient
A11	Experiencer T45 Patient
A12	Experiencer T46 Patient
A13	Experiencer T47 Patient
